Balancing efficacy and safety in anticoagulation can be a challenge, especially for high-risk patients such as those with severe renal impairment1. Sometimes, real world evidence can also conflict with results from randomised controlled trials.
Join Dr Chris Hammett, an interventional cardiologist at the Royal Brisbane and Women’s Hospital and Professor Jan Beyer-Westendorf, Head of the Thrombosis Research Unit at the University Hospital Carl Gustav Carus, Dresden, Germany for a discussion on how to navigate the common myths and misperceptions of anticoagulation.
There will be an opportunity to ask questions during the webinar.
Associate Professor Jan Beyer-Westendorf
University Hospital Carl Gustav Carus Dresden, Germany
Dr Jan Beyer-Westendorf specialises in intensive care medicine, vascular medicine and haemostaseology. His research interests mainly focus on venous thromboembolism, atrial fibrillation, anticoagulant therapies and bleeding management.
Dr Chris Hammett
Royal Brisbane and Women’s Hospital, QLD.
Dr Chris Hammett has a major interest in cardiovascular research and has an ongoing interest in the role of antithrombotic therapy for both improving outcomes in ACS, and stroke prevention for atrial fibrillation. He has been the principal investigator in many landmark trials on novel antiplatelet and antithrombotic agents for both ACS and AF.
This webinar has been produced by Bayer Australia Limited. Bayer endorses the Medicines Australia Code of Conduct and all activities conducted as part of this meeting must comply with the Code. Some presentations may refer to products or indications not approved in your country. Please refer to the approved Product Information before prescribing. The views and opinions expressed throughout this meeting are those of the speaker and do not necessarily represent the views, policy or position of Bayer.
- Reinecke H. Dilemmas in the Management of Atrial Fibrillation in Chronic Kidney Disease. J Am Soc Nephrol 20: 705–711, 2009.